A Two-Year Real-Life Study

Matteo Megna,Angelo Ruggiero,Fabrizio Martora,Ylenia Vallone,Gianluca Guerrasio,Luca Potestio

DOI: https://doi.org/10.3390/jcm13092691

IF: 3.9

2024-05-04

Journal of Clinical Medicine

Abstract:Guselkumab is the first approved human IgG1λ monoclonal antibody selectively targeting the p19 subunit of interleukin (IL)-23. Despite its effectiveness and safety, which have been widely reported by clinical trials and real-life experiences, data regarding its use on patients who previously failed anti-IL17 are limited or characterized by a reduced follow-up period. These data are essential to guide clinicians in biologic switching, considering that anti-IL23 and anti-IL17 partially share their therapeutic targets, as well as some patients who may have to interrupt treatment with anti-IL17 for loss of efficacy over time or the development of adverse events (AEs). In this context, we performed a retrospective study with the aim of evaluating the long-term use (2 years) of guselkumab in psoriasis patients who previously failed at least one anti-IL17 in a real-life setting, also focusing attention on psoriasis located in difficult-to-treat areas (the scalp, palms or soles, fingernails, genitals). A total of 61 patients (35 male, 57.4%; mean age 57.6 ± 8.8 years) were enrolled. Of these, 30 (49.2%) patients failed secukinumab, 21 (34.4%) failed ixekizumab, 7 (11.5%) failed brodalumab, and 3 (4.9%) failed both secukinumab and ixekizumab. At the baseline, the mean PASI and BSA were 12.8 ± 8.4 and 24.5 ± 26.6, respectively. During week 16, PASI90 and PASI100 responses were achieved by 60.7% and 37.7% of patients, respectively, which continued to improve up to week 104 (PASI90: 73.8%, PASI100: 59.0%). Clinical improvement in difficult-to-treat areas was detected as well. In particular, a slower improvement for fingernails and the palmoplantar region was reported compared to scalp and genital psoriasis at week 16. However, no differences were found following 28 weeks of therapy. Primary and secondary inefficacy were reported by 1 (1.6%) and 5 (8.2%) patients. As regards safety, no severe AEs were collected.

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the long - term efficacy and safety of guselkumab in psoriasis patients who have failed IL - 17 inhibitor treatment. Specifically, the study aims to:

1. **Evaluate long - term efficacy**: Through a two - year real - world study, evaluate the long - term efficacy of guselkumab in psoriasis patients who have failed IL - 17 inhibitor treatment, especially the effect on difficult - to - treat areas (such as the scalp, palms or soles, nails, genitals).

2. **Evaluate safety**: Study the safety of guselkumab in these patients, including whether serious adverse events (AEs) will occur.

3. **Compare the effects in different treatment failure situations**: Analyze the differences in efficacy of patients who have failed treatment with different IL - 17 inhibitors (such as secukinumab, ixekizumab, brodalumab) after receiving guselkumab treatment.

4. **Provide clinical guidance**: Provide a reference for clinicians when choosing biologic agent conversion therapy. Especially in the case where IL - 17 and IL - 23 partially share treatment targets, understanding the efficacy and safety of guselkumab is of great significance for guiding treatment decisions.

Through these objectives, the study hopes to provide more evidence for clinicians to better manage and treat psoriasis patients who have failed IL - 17 inhibitor treatment.